Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares vs. Eli Lilly & Co.
KNSA
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares
$76.06 -0.59%
VS LLYEli Lilly & Co.
$1185.71 -0.52%
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares and Eli Lilly & Co. are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| KNSA | LLY | |
|---|---|---|
| Market Cap | $5.93 billion | $1.06 trillion |
| Revenue (TTM) | — | $79.67 billion |
| Net Income (TTM) | — | $26.71 billion |
LLY leads on 1 of 1 size & scale factors.
Valuation
| KNSA | LLY | |
|---|---|---|
| P/E Ratio | — | 39.80 |
| Price / Book | — | 31.20 |
| Price / Sales | — | 13.27 |
KNSA and LLY split the valuation factors evenly.
Profitability
| KNSA | LLY | |
|---|---|---|
| Net Margin | — | 33.53% |
| Return on Equity | — | 78.84% |
KNSA and LLY split the profitability factors evenly.
Dividend
| KNSA | LLY | |
|---|---|---|
| Dividend Yield | — | 0.58% |
| Payout Ratio | — | 23.23 |
KNSA and LLY split the dividend factors evenly.
Risk & Sentiment
| KNSA | LLY | |
|---|---|---|
| Short Interest | 0.02% | 1.29% |
KNSA leads on 1 of 1 risk & sentiment factors.
Dig deeper: KNSA overview, KNSA financials, LLY overview, LLY financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.